Delivery Order SPE2DB22D1017-SPE2DB25FG4JS
- Not listed
- The Defense Logistics Agency awarded a $3,193.50 firm fixed price delivery order to AmerisourceBergen Drug Corp for Brimonidine Tartrate 0.15% ophthalmic drops (10mL) on September 19, 2025, with an ultimate completion date of September 22, 2025. This non-set-aside competitive award was fulfilled by AmerisourceBergen's Corporate Office division, with performance to be completed at the vendor's Conshohocken, Pennsylvania location. The delivery order represents a child contract under...
- The Defense Logistics Agency awarded a delivery order valued at $4,237.09 to AmerisourceBergen Drug Corp for Brimonidine Tartrate 0.15% ophthalmic drops (15mL) on August 26, 2025, with an ultimate completion date of August 27, 2025. This firm fixed-price delivery order represents a competitively awarded, non-set-aside contract with performance at the contractor's Conshohocken, Pennsylvania facility. The award falls under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a $1,960.01 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Brimonidine Tartrate 0.1% ophthalmic drops (5mL) with an ultimate completion date of July 31, 2025. This delivery order, issued on July 30, 2025, is classified as a child contract and was awarded without a set-aside designation through competitive procurement. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Brimonidine...
- This is a delivery order awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) for the supply of Brimonidine Tartrate 0.15% ophthalmic drops. The $1,957.02 firm fixed-price contract has an ultimate completion date of April 10, 2024. AmerisourceBergen is a for-profit organization that has established itself as a key vendor for federal healthcare programs, particularly within military and veterans' healthcare systems. The company holds...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on June 13, 2025, for the supply of Brimonidine-Timolol 0.2%-0.5% ophthalmic medication in a 10 mL formulation, with a ceiling value of $73,571.23. This competitively awarded, firm fixed-price delivery order is scheduled for completion by June 16, 2025, and will be fulfilled from the contractor's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation,...
- The Defense Logistics Agency awarded a delivery order valued at $4,256.19 to AmerisourceBergen Drug Corp for the supply of Brimonidine-Timolol 0.2%-0.5% ophthalmic solution in a 10 milliliter formulation, with completion expected by August 29, 2025. This non-set-aside, competitively awarded contract employs firm fixed pricing and represents a child order under AmerisourceBergen's larger indefinite delivery contract vehicle with DLA Troop Support Medical. The pharmaceutical product will be...
- The Defense Logistics Agency awarded a delivery order valued at $1,145.90 to AmerisourceBergen Drug Corp for Brimonidine-Timolol 0.2%-0.5% ophthalmic solution (10ml), with an ultimate completion date of August 4, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded to support federal medical supply requirements. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,774.84 delivery order contract is for the supply of brimonidine tartrate 0.15% eye drops, a medication used to treat glaucoma. The contract is a Firm Fixed Price (FFP) delivery order that is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 between AmerisourceBergen and the DLA Troop...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The $1,745.53 firm fixed-price delivery order is for the supply of Brimonidine-Timolol 0.2%-0.5% eye drops in 10 mL bottles. The contract has an ultimate completion date of October 22, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
- The Defense Logistics Agency awarded a $1,470 delivery order to Amerisourcebergen Drug Corporation for brimonidine 0.2% eye drops. As the prime contractor, Amerisourcebergen will supply 5mL bottles of the ophthalmic solution to support DLA programs. Performance will occur at Amerisourcebergen's facility in Conshohocken, Pennsylvania over a one-day period in late September 2023. The firm fixed price contract utilizes no set-aside designations and is issued against an existing DLA-wide supply...
- SPE2DB22D1017Indefinite Delivery Contract
- SPE2DB22D1017-SPE2DB25FG4JSDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,240.86 to AmerisourceBergen Drug Corp on June 5, 2025, for the supply of Brimonidine Tartrate 0.15% ophthalmic drops in 10ml units. This is a firm fixed price contract with no set-aside designation, performed at the contractor's facility in Conshohocken, Pennsylvania, with an ultimate completion date of June 6, 2025. The award represents a competitive procurement under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract with DLA Troop Support Medical (contract number SPE2DX), a comprehensive pharmaceutical supply vehicle valued at $999,999,999 and extending through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. As a child delivery order under the larger IDC, this award demonstrates the contractor's ongoing capability to fulfill federal pharmaceutical requirements through open competition. The company's extensive portfolio encompasses brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains, enabling it to provide flexible support to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 6/5/25 |